An open-label, multicenter, randomized, parallel, single-dose, comparative bioavailability study of two triamcinolone hexacetonide injectable suspensions in patients with knee osteoarthritis


  • Kaushal Anand Department of Orthopedics, B.J. Medical College and Civil Hospital, Asarwa, Ahmedabad, Gujarat, India
  • Praganesh Kumar GSVM Medical College, Kanpur, Uttar Pradesh, India
  • Sameer Haveri KLE’s Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi, Karnataka, India
  • Shivani Acharya Abbott India Ltd., Mumbai, Maharashtra, India
  • Anadya P. Tripathi Abbott India Ltd., Mumbai, Maharashtra, India
  • Milind Bhole Abbott Healthcare Pvt Ltd, Mumbai, Maharashtra, India
  • Deeksha Malhotra Abbott Healthcare Pvt Ltd, Mumbai, Maharashtra, India



Knee osteoarthritis, Pain, Systemic exposure, Triamcinolone acetonide, Triamcinolone hexacetonide


Background: Triamcinolone hexacetonide (THA), a synthetic glucocorticoid with low solubility, can provide sustained pain relief and less systemic side effects in patients with knee osteoarthritis. This study aimed to characterize pharmacokinetic profile of THA-test product containing 20 mg/ml injectable suspension and compare its bioavailability with the standard reference in Indian patients with knee osteoarthritis.

Methods: In this open-label, randomized, multicenter study, 44 adult patients were randomized (1:1; test n=23, reference n=21) to receive a single dose of test or reference products. The primary objective was to characterize the pharmacokinetic profile and compare bioavailability of both products via serum triamcinolone acetonide (TCA) concentration. Secondary objectives included safety and tolerability evaluation, impact on hypothalamic-pituitary-adrenal axis, and efficacy of test and reference products in reducing index knee pain.

Results: Both products were absorbed with a median Tmax of 23.9 hours. Comparative bioavailability analysis demonstrated no statistically significant formulation effect for ln-transformed Cmax (1098.052 pg/ml for test, 1333.850 pg/ml for reference) and AUC0-t (159112.561 pg×h/ml for test, 211531.035 pg×h/ml for reference) for TCA. T/R ratio for Cmax was 82.3% and T/R ratio for AUC0-t was 75.2%, with >100% inter-subject variability for both Cmax and AUC0-t. Additionally, recovery time of cortisol levels of test and reference arms was 96 hours and 456 hours, respectively. Both products significantly reduced knee pain (p<0.0001).

Conclusions: The test product provided lower systemic exposure and faster recovery of serum cortisol levels than the reference, while still providing similar beneficial effect in sustained index knee pain reduction.


Wang Q, Mol MF, Bos PK, Dorleijn DMJ, Vis M, Gussekloo J, et al. Effect of intramuscular vs intra-articular glucocorticoid injection on pain among adults with knee osteoarthritis: The KIS randomized clinical trial. JAMA Netw Open. 2022;5(4):e224852.

Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. E Clinical Medicine. 2020;29-30:100587.

Singh A, Das S, Chopra A, Danda D, Paul BJ, March L, et al. Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019. Osteoarth Cartil 2022;30(8):1070-8.

Pal CP, Singh P, Chaturvedi S, Pruthi KK, Vij A. Epidemiology of knee osteoarthritis in India and related factors. Indian J Orthop. 2016;50(5):518-22.

Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55.

Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-74.

Kim HS. Recommended and real-world treatment of knee osteoarthritis in Korea: differences and compromises. Korean J Intern Med. 2019;34(5):985-8.

Rubin S, Ohana O, Goldberg O, Peled O, Gendler Y, Habot-Wilner Z, et al. The efficacy and safety of intra-articular injection of triamcinolone acetonide versus triamcinolone hexacetonide for treatment of juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2022;20(1):5.

Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5(9):730-9.

Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. World J Orthop. 2014;5(3):351-61.

Derendorf H, Möllmann H, Grüner A, Haack D, Gyselby G. Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986;39(3):313-7.

Langworthy MJ, Conaghan PG, Ruane JJ, Kivitz AJ, Lufkin J, Cinar A, et al. Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis. Adv Ther. 2019;36(6):1398-411.

Ross E, Katz NP, Conaghan PG, Kivitz A, Turk DC, Spitzer AI, et al. Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain Scales. Pain Ther. 2022;11(1):289-302.

EMC. Triamcinolone hexacetonide 20 mg/ml suspension for injection. 2022. Available at: Accessed on 07 February 2023.

Garg N, Perry L, Deodhar A. Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids. Clin Rheumatol. 2014;33(12):1695-706.

FDA. Aristospan® (Triamcinolone Hexacetonide Injectable Suspension, USP) 5 mg/mL PARENTERAL. Available at: https://www. Accessed on 07 February 2023.

Zulian F, Martini G, Gobber D, Plebani M, Zacchello F, Manners P. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford). 2004;43(10):1288-91.

Coll S, Matabosch X, Llorente-Onaindia J, Carbó ML, Pérez-Mañá C, Monfort N, et al. Elimination profile of triamcinolone hexacetonide and its metabolites in human urine and plasma after a single intra-articular administration. Drug Test Anal. 2019;11(11-12):1589-600.

Kohn MD, Sassoon AA, Fernando ND. Classifications in Brief: Kellgren-Lawrence Classification of Osteoarthritis. Clin Orthop Relat Res. 2016;474(8):1886-93.

Rudnik-Jansen I, Schrijver K, Woike N, Tellegen A, Versteeg S, Emans P, et al. Intra-articular injection of triamcinolone acetonide releasing biomaterial microspheres inhibits pain and inflammation in an acute arthritis model. Drug Deliv. 2019;26(1):226-36.

Chun A, Muhammad LN, De Ranieri D. Comparison of efficacy between triamcinolone acetonide and triamcinolone hexacetonide for intraarticular therapy in juvenile idiopathic arthritis: a retrospective analysis. BMC Rheumatol. 2022;6(1):18.

Lomonte AB, de Morais MG, de Carvalho LO, Zerbini CA. Efficacy of triamcinolone hexacetonide versus methylprednisolone acetate intraarticular injections in knee osteoarthritis: A randomized, double-blinded, 24-week study. J Rheumatol. 2015;42(9):1677-84.

Brombini GC, Rahal SC, Fabro AT, Santos I, Tsunemi MH, Joaquim JGF, et al. Use of hyaluronic acid associated with triamcinolone acetonide or ozone gas in the treatment of induced osteoarthritis in rabbits. Acta Cir Bras. 2021;36(12):e361201.

Dickson RR, Reid JM, Nicholson WT, Lamer TJ, Hooten WM. Corticosteroid and cortisol serum levels following intra-articular triamcinolone acetonide lumbar facet joint injections. Pain Pract. 2018;18(7):864-70.

Oo WM, Liu X, Hunter DJ. Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis. Expert Opin Drug Metab Toxicol. 2019;15(12):1021-32.

Rensen N, Gemke RJ, van Dalen EC, Rotteveel J, Kaspers GJ. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia. Cochrane Database Syst Rev. 2017;11(11):Cd008727.

McMillin M, Frampton G, Quinn M, Divan A, Grant S, Patel N, et al. Suppression of the HPA Axis During Cholestasis Can Be Attributed to Hypothalamic Bile Acid Signaling. Mol Endocrinol. 2015;29(12):1720-30.






Original Research Articles